{"id":70487,"date":"2026-07-23T21:13:45","date_gmt":"2026-07-23T13:13:45","guid":{"rendered":"https:\/\/flcube.com\/?p=70487"},"modified":"2026-07-23T21:13:46","modified_gmt":"2026-07-23T13:13:46","slug":"haisco-pharma-secures-nmpa-approval-for-hsk39297-first-oral-cfb-inhibitor-for-paroxysmal-nocturnal-hemoglobinuria-in-china","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=70487","title":{"rendered":"Haisco Pharma Secures NMPA Approval for HSK39297 \u2013 First Oral CFB Inhibitor for Paroxysmal Nocturnal Hemoglobinuria in China"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Haisco Pharmaceutical Group Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/002653:SHE\">SHE: 002653<\/a>) announced that China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong> has granted <strong>marketing approval<\/strong> for <strong>HSK39297<\/strong>, a <strong>Category 1 innovative oral small-molecule inhibitor of Complement Factor B (CFB)<\/strong> indicated for the treatment of adult patients with <strong>paroxysmal nocturnal hemoglobinuria (PNH)<\/strong> who have not previously received complement inhibitor therapy.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone\" class=\"wp-block-heading\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>Full marketing approval, Category 1 innovative drug<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>HSK39297 tablets (oral, once daily)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Treatment of adult PNH patients na\u00efve to complement inhibitor therapy<\/td><\/tr><tr><td><strong>Approval Date<\/strong><\/td><td>23 Jul 2026<\/td><\/tr><tr><td><strong>Disclosure Assurance<\/strong><\/td><td>Company and Board guarantee information accuracy and completeness<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> Highly potent and selective oral small-molecule inhibitor of <strong>Complement Factor B (CFB)<\/strong><\/li>\n\n\n\n<li><strong>Target:<\/strong> <strong>Proximal link of the alternative pathway<\/strong> in the complement cascade<\/li>\n\n\n\n<li><strong>Innovation:<\/strong> First-in-class therapy enabling <strong>&#8220;full-chain&#8221; intervention<\/strong> against PNH hemolysis by simultaneously inhibiting terminal complement-driven intravascular hemolysis and controlling C3b-mediated extravascular hemolysis<\/li>\n\n\n\n<li><strong>Therapeutic Effect:<\/strong> Blocks activation of the alternative pathway (AP) and complement amplification loop, suppressing overall complement pathway activity at its source<\/li>\n\n\n\n<li><strong>Administration:<\/strong> Once-daily oral tablet designed to improve long-term patient compliance<\/li>\n\n\n\n<li><strong>Development Status:<\/strong> Independently developed by Haisco Pharma with potential applications across various diseases mediated by abnormal complement activation<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>PNH Treatment Landscape:<\/strong> Current PNH therapies primarily target terminal complement components; HSK39297&#8217;s proximal targeting represents a paradigm shift in disease management<\/li>\n\n\n\n<li><strong>Patient Population:<\/strong> China has an estimated 5,000-8,000 PNH patients, with significant unmet need for oral therapies that address both intravascular and extravascular hemolysis<\/li>\n\n\n\n<li><strong>Competitive Advantage:<\/strong> As the first oral CFB inhibitor approved in China, HSK39297 offers superior convenience over intravenous alternatives while providing comprehensive hemolysis control<\/li>\n\n\n\n<li><strong>Commercial Strategy:<\/strong> Haisco plans to leverage its established hospital distribution network to ensure rapid market penetration among hematologists and specialized treatment centers<\/li>\n\n\n\n<li><strong>Pipeline Potential:<\/strong> The CFB inhibition platform may support expansion into other complement-mediated diseases including atypical hemolytic uremic syndrome (aHUS) and C3 glomerulopathy<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding regulatory timelines, clinical outcomes, and commercial expectations for HSK39297. Haisco Pharmaceutical Group Co., Ltd. and all members of the Board of Directors guarantee that the disclosed information is true, accurate, and complete, containing no false records, misleading statements, or material omissions. Actual results may differ due to risks including market adoption, competitive dynamics, and regulatory requirements.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/\u6d77\u601d\u79d1\uff1a\u5173\u4e8e\u521b\u65b0\u836f\u7425\u73c0\u9178\u601d\u666e\u53ef\u6cee\u7247\u83b7\u6279\u4e0a\u5e02\u7684\u516c\u544a.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of \u6d77\u601d\u79d1\uff1a\u5173\u4e8e\u521b\u65b0\u836f\u7425\u73c0\u9178\u601d\u666e\u53ef\u6cee\u7247\u83b7\u6279\u4e0a\u5e02\u7684\u516c\u544a.\"><\/object><a id=\"wp-block-file--media-2ce7f232-e180-4300-8984-484106a17e11\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/\u6d77\u601d\u79d1\uff1a\u5173\u4e8e\u521b\u65b0\u836f\u7425\u73c0\u9178\u601d\u666e\u53ef\u6cee\u7247\u83b7\u6279\u4e0a\u5e02\u7684\u516c\u544a.pdf\">\u6d77\u601d\u79d1\uff1a\u5173\u4e8e\u521b\u65b0\u836f\u7425\u73c0\u9178\u601d\u666e\u53ef\u6cee\u7247\u83b7\u6279\u4e0a\u5e02\u7684\u516c\u544a<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/\u6d77\u601d\u79d1\uff1a\u5173\u4e8e\u521b\u65b0\u836f\u7425\u73c0\u9178\u601d\u666e\u53ef\u6cee\u7247\u83b7\u6279\u4e0a\u5e02\u7684\u516c\u544a.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-2ce7f232-e180-4300-8984-484106a17e11\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Haisco Pharmaceutical Group Co., Ltd. (SHE: 002653) announced that China&#8217;s National Medical Products Administration (NMPA)&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[139,15,24,929],"class_list":["post-70487","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-haisco-pharmaceutical","tag-product-approvals","tag-rare-orphan-disease-drugs","tag-she-002653"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.1) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Haisco Pharma Secures NMPA Approval for HSK39297 \u2013 First Oral CFB Inhibitor for Paroxysmal Nocturnal Hemoglobinuria in China - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Haisco Pharmaceutical Group Co., Ltd. (SHE: 002653) announced that China&#039;s National Medical Products Administration (NMPA) has granted marketing approval for HSK39297, a Category 1 innovative oral small-molecule inhibitor of Complement Factor B (CFB) indicated for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH) who have not previously received complement inhibitor therapy.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=70487\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Haisco Pharma Secures NMPA Approval for HSK39297 \u2013 First Oral CFB Inhibitor for Paroxysmal Nocturnal Hemoglobinuria in China\" \/>\n<meta property=\"og:description\" content=\"Haisco Pharmaceutical Group Co., Ltd. (SHE: 002653) announced that China&#039;s National Medical Products Administration (NMPA) has granted marketing approval for HSK39297, a Category 1 innovative oral small-molecule inhibitor of Complement Factor B (CFB) indicated for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH) who have not previously received complement inhibitor therapy.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=70487\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-23T13:13:45+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-23T13:13:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70487#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70487\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Haisco Pharma Secures NMPA Approval for HSK39297 \u2013 First Oral CFB Inhibitor for Paroxysmal Nocturnal Hemoglobinuria in China\",\"datePublished\":\"2026-07-23T13:13:45+00:00\",\"dateModified\":\"2026-07-23T13:13:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70487\"},\"wordCount\":403,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Haisco Pharmaceutical\",\"Product approvals\",\"Rare \\\/ orphan disease drugs\",\"SHE: 002653\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70487#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70487\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=70487\",\"name\":\"Haisco Pharma Secures NMPA Approval for HSK39297 \u2013 First Oral CFB Inhibitor for Paroxysmal Nocturnal Hemoglobinuria in China - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-07-23T13:13:45+00:00\",\"dateModified\":\"2026-07-23T13:13:46+00:00\",\"description\":\"Haisco Pharmaceutical Group Co., Ltd. (SHE: 002653) announced that China's National Medical Products Administration (NMPA) has granted marketing approval for HSK39297, a Category 1 innovative oral small-molecule inhibitor of Complement Factor B (CFB) indicated for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH) who have not previously received complement inhibitor therapy.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70487#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70487\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70487#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Haisco Pharma Secures NMPA Approval for HSK39297 \u2013 First Oral CFB Inhibitor for Paroxysmal Nocturnal Hemoglobinuria in China\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Haisco Pharma Secures NMPA Approval for HSK39297 \u2013 First Oral CFB Inhibitor for Paroxysmal Nocturnal Hemoglobinuria in China - Insight, China&#039;s Pharmaceutical Industry","description":"Haisco Pharmaceutical Group Co., Ltd. (SHE: 002653) announced that China's National Medical Products Administration (NMPA) has granted marketing approval for HSK39297, a Category 1 innovative oral small-molecule inhibitor of Complement Factor B (CFB) indicated for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH) who have not previously received complement inhibitor therapy.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=70487","og_locale":"en_US","og_type":"article","og_title":"Haisco Pharma Secures NMPA Approval for HSK39297 \u2013 First Oral CFB Inhibitor for Paroxysmal Nocturnal Hemoglobinuria in China","og_description":"Haisco Pharmaceutical Group Co., Ltd. (SHE: 002653) announced that China's National Medical Products Administration (NMPA) has granted marketing approval for HSK39297, a Category 1 innovative oral small-molecule inhibitor of Complement Factor B (CFB) indicated for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH) who have not previously received complement inhibitor therapy.","og_url":"https:\/\/flcube.com\/?p=70487","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-07-23T13:13:45+00:00","article_modified_time":"2026-07-23T13:13:46+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=70487#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=70487"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Haisco Pharma Secures NMPA Approval for HSK39297 \u2013 First Oral CFB Inhibitor for Paroxysmal Nocturnal Hemoglobinuria in China","datePublished":"2026-07-23T13:13:45+00:00","dateModified":"2026-07-23T13:13:46+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=70487"},"wordCount":403,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Haisco Pharmaceutical","Product approvals","Rare \/ orphan disease drugs","SHE: 002653"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=70487#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=70487","url":"https:\/\/flcube.com\/?p=70487","name":"Haisco Pharma Secures NMPA Approval for HSK39297 \u2013 First Oral CFB Inhibitor for Paroxysmal Nocturnal Hemoglobinuria in China - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-07-23T13:13:45+00:00","dateModified":"2026-07-23T13:13:46+00:00","description":"Haisco Pharmaceutical Group Co., Ltd. (SHE: 002653) announced that China's National Medical Products Administration (NMPA) has granted marketing approval for HSK39297, a Category 1 innovative oral small-molecule inhibitor of Complement Factor B (CFB) indicated for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH) who have not previously received complement inhibitor therapy.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=70487#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=70487"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=70487#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Haisco Pharma Secures NMPA Approval for HSK39297 \u2013 First Oral CFB Inhibitor for Paroxysmal Nocturnal Hemoglobinuria in China"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70487","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=70487"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70487\/revisions"}],"predecessor-version":[{"id":70489,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70487\/revisions\/70489"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=70487"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=70487"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=70487"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}